The AKR1B1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the HT29 human colorectal adenocarcinoma cell line, featuring targeted disruption of the AKR1B1 gene. This polyclonal pool comprises a heterogeneous mix of cells bearing diverse loss-of-function alleles, generated by Cas9-mediated double-strand breaks and subsequent repair. It offers a robust model for studying AKR1B1 function without single-cell cloning artifacts, enabling population-level phenotypic analyses. The cells are supplied as a ready-to-use reagent for metabolic and cancer research applications.
The HT29 cell line originates from a human colorectal adenocarcinoma and serves as a widely used intestinal epithelial model. These adherent epithelial cells maintain characteristics such as mucin production, polarization ability, and expression of tight junction proteins, making them suitable for investigating colorectal cancer progression, intestinal physiology, and drug absorption. HT29 cells are extensively applied in studies of proliferation, differentiation, and chemosensitivity, providing a relevant background for examining the consequences of AKR1B1 loss in a tumor-derived context.
AKR1B1 encodes aldose reductase, the rate-limiting enzyme of the polyol pathway, which reduces glucose to sorbitol using NADPH as a cofactor. The sorbitol is then converted to fructose by sorbitol dehydrogenase (SORD). Beyond glucose metabolism, AKR1B1 detoxifies reactive aldehydes from lipid peroxidation. The gene is transcriptionally regulated by high glucose, hyperosmotic stress, Nrf2, AP-1, and NF-??B. Its enzymatic activity consumes NADPH and generates sorbitol and fructose, thereby influencing cellular osmolarity and redox balance. AKR1B1 interacts directly with glucose and NADPH, and its disruption impacts downstream aldehyde levels and NADP+/NADPH ratios.
In HT29 colorectal cancer cells, AKR1B1 knockout is particularly relevant because the polyol pathway may support cancer cell proliferation, chemoresistance, and oxidative stress responses. By eliminating aldose reductase activity, these polyclonal knockout cells are expected to exhibit reduced sorbitol accumulation, altered NADPH consumption, and impaired detoxification of aldehydes such as 4-hydroxynonenal. This model facilitates dissection of the polyol pathway??s contribution to colorectal tumor cell metabolism and can be used to investigate how metabolic reprogramming affects malignant phenotypes under normoxic and stress conditions.
Researchers can employ this polyclonal knockout cell population in diverse assays, including western blot and RT-qPCR for confirming AKR1B1 disruption, sorbitol quantification and NADP+/NADPH measurement to assess metabolic flux, and MTT proliferation, migration, and drug sensitivity (e.g., cisplatin) assays to evaluate functional consequences. Key research applications include studying the polyol pathway in colorectal cancer, elucidating AKR1B1??s role in chemoresistance, screening aldose reductase inhibitors, and performing metabolic flux analysis. For further details, please contact Ascent Research.
